anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Table

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 60,568
Current window 47,251-47,280
Pages 2,019
Rows per page 30
Component: Tableclear collectionreset all
18 30 60

Component

47,251-47,280 of 60,568

filter-aware
17
Front | Start Up Pitch Deck | 21 slidesFront | Start Up Pitch Deck | 21 slides · Front
Pitch deck Investor relations 1 hit
18
Front | Start Up Pitch Deck | 21 slidesFront | Start Up Pitch Deck | 21 slides · Front
Pitch deck Investor relations 1 hit
25
The table displays percentage premiums, with negative values in parentheses indicating a discount for voting shares or a premium for non-voting shares.LionTree | Investment Banking Pitch Book | 25 slides · LionTree
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
29
The table shows adjustments for Stock-Based Compensation (SBC) and non-recurring tax expenses.Shopify | Start Up Pitch Deck | 29 slides · Shopify
Pitch deck Investor relations 1 hit
34
The study design follows the CLSI EP05-A3 standard.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
36
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
37
The slide references CLSI EP09-A3, a standard for method comparison and bias estimation using patient samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
40
The slide includes a disclaimer at the bottom regarding FDA clearance.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
41
The slide uses a table to validate performance against industry-standard benchmarks.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
44
References CLSI EP05-A3 standard.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
45
The slide includes a disclaimer about FDA clearance status and definitions for (L) and (H) samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
46
The slide outlines the clinical study parameters for a Herpes diagnostic test.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
47
Includes FDA clearance references and disclaimer.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
52
References CLSI EP05-A3 standard for precision performance testing.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
53
Includes FDA disclaimer and definitions for (L) and (N) cell counts.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
54
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
57
Includes technical definitions of error metrics and regulatory disclaimers.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
61
The slide compares the assay's LoD (480 copies/mL) against the CDC Zika test LoD (930 copies/mL).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
62
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
63
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
64
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
65
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
66
The slide presents experimental validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
67
Includes a standard Theranos FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
68
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
73
This slide outlines technical mitigation strategies for blood sample collection issues.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
79
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
01
Slide 1
Includes footnotes detailing intercompany rent consolidations and specific regional definitions.Toys R Us | Results Presentation Deck | 5 slides · Toys R Us
Regulatory filing Investor relations 1 hit
04
The table reconciles operating earnings to Adjusted EBITDA by adding back various expenses and adjustments, further adjusted for intercompany items.Toys R Us | Results Presentation Deck | 5 slides · Toys R Us
Regulatory filing Investor relations 1 hit
05
The table includes specific line items for non-recurring charges like goodwill impairment and store closure costs.Toys R Us | Results Presentation Deck | 5 slides · Toys R Us
Regulatory filing Investor relations 1 hit